Abstract
The prevalence of peripheral arterial occlusive disease (PAD) in women and men is equal. Studies to date present conflicting data of gender effects on the risk factors, clinical presentation, and treatment outcomes. Clinical trials have often failed to analyze results by gender or to recruit sufficient women to enable such an analysis. This review summarizes the management and outcome of limb salvage therapy with a particular focus in women.

Introduction
Cardiovascular diseases remain the number one cause of death in industrialized countries. For decades, it was thought that cardiovascular diseases affect men predominantly. Whether due to better disease recognition, increased numbers of women smoking tobacco, or other socioeconomic or environmental factors, the reported incidence of cardiovascular diseases in women began to rise in the early 1980s. In 2007, more women died from cardiovascular diseases than men (421,918 vs. 381,986, respectively). In fact, according to the National Center for Health Statistics, the annual number of cardiovascular deaths for women in the United States has consistently exceeded those for men since 1984. During the same period, a rise in the incidence of peripheral arterial occlusive disease (PAD) was also observed in women. Published PAD studies have reported conflicting results on the outcome for limb salvage, morbidity, and mortality in women compared to men. Factors such as older age, late presentation, delayed diagnosis, smaller-size vessels, and other gender-related biases have been postulated to account, at least in part, for the portended less-favorable outcome in women with PAD. However, until recently, most studies on PAD have had low enrollment rates for women. Fortunately, the gender disparity in the management of PAD has been recognized, and more effort and resources have been dedicated to study this issue. In this article, we provide an up-to-date review on PAD in women, focusing on the similarities and differences compared to men with regard to clinical presentation and limb-salvage treatment.

Epidemiology, Risk Factors, and Clinical Evaluation

Prevalence of PAD in Women
PAD affects approximately 8 to 12 million people in the United States. The prevalence of PAD varies depending on what is defined as PAD and the age of the study population. Through mechanisms not yet well defined, premenopausal women are thought to be relatively protected from atherosclerosis. However, arterial occlusive disease in women increases significantly during menopause and after. As such, the incidence of disease in women and men in their sixth and seventh decades is at least identical. The prevalence of PAD rises with age in both men and women.

Risk Factors for PAD in Women
Well-defined risk factors of PAD include older age (>65 years), cigarette smoking, systemic hypertension, diabetes, dyslipidemia, and homocysteinemia. The patient’s ethnicity and socio-economic status have been associated with higher PAD complications. In a German population-based study, participants with low and median educational levels had higher odds of suffering from PAD compared to participants with high educational levels. In this study, the association of lower socioeconomic status and PAD was more influenced by current smoking status, diabetes, and obesity rather than by actual financial income. In a retrospective review of a cohort of more than 1500 patients, Robinson et al. showed that Hispanic race was an independent risk factor for limb loss in patients undergoing infrainguinal bypass surgery. In the posthoc analysis of the PREVENT III trial, a multicenter randomized trial that evaluated the results of leg bypass surgery for critical ischemia using venous conduits, graft failure and amputation rates were highest in black women, suggesting a synergistic effect of gender and race on outcome.

Clinical Presentation and Evaluation of PAD in Women
Symptoms of PAD range from intermittent leg claudication and ischemic rest pain to tissue loss or necrosis. However, the
greater mobility loss than men, as recently shown by McDermott with PAD may also demonstrate a faster functional decline and smoked or continue to smoke tobacco compared to men.13 Women had a higher incidence of metabolic syndrome, obesity, the presence of ischemic rest pain, nonhealing wounds, or tissue necrosis (such as hair loss, muscle atrophy, or thickened nail), and the presence or absence of tissue loss and necrosis (Figures 1 A, B). Although much has been reported on the higher incidence of cardiovascular events in patients with asymptomatic PAD, the natural history with regard to limb outcome in these patients is not well defined. Fortunately, it has been observed that only a small percentage of patients with asymptomatic PAD or intermittent claudication will develop progressive disease or critical limb-threatening ischemia. Several PAD reports have found women to be older (typically by 3 to 4 years) and to present with more severe or advanced disease compared to men. Brevetti et al. reported on a cohort of 231 men and women with PAD.13 The authors found that women had a higher incidence of metabolic syndrome, obesity, diabetes mellitus, and hypertension but were less likely to have smoked or continue to smoke tobacco compared to men.13 Women with PAD may also demonstrate a faster functional decline and greater mobility loss than men, as recently shown by McDermott et al.14

Modification of risk factors and medical therapy remain the first line of treatment for all patients with PAD.5, 16, 17 In brief, a smoking cessation program should be instituted in all active smokers. Continued tobacco smoking has been associated with a higher risk of amputation in patients with intermittent claudication, lower patency in leg bypass grafts, and increased risk of myocardial infarction and death.18-20 Patients with intermittent claudication should be encouraged to continue to exercise. Furthermore, participation in a supervised exercise program has been shown to produce superior symptomatic improvement in these patients compared to unsupervised exercise.21-22 Medical therapy aims at keeping the HgbA1c level to less than 7% in diabetic patients, reducing serum low-density lipoprotein cholesterol level to less than 70 mg/dL in patients with hypercholesterolemia, and lowering the blood pressure to less than 130/80 mm Hg in hypertensive patients.23-26 In addition, antiplatelet, statin, and angiotensin-converting enzyme inhibitor, and β-blockade agents have all been shown to be beneficial in PAD patients.27 We therefore recommend prescribing these agents to all PAD patients unless otherwise contraindicated. Moreover, the addition of cilostazol, a phosphodiesterase inhibitor, can further improve exercise capacity and increase walking distance in patients with intermittent claudication.33, 34

We found no reported significant differences regarding medical treatments for PAD in women compared to men. However, there are two important points related to prescription medications to consider. First is the observation that hormone replacement therapy, either as estrogen alone or in combination with progesterone, has been shown to increase cardiovascular risk without improving PAD.35, 36 Additionally, it has been shown that lower income is associated with worse PAD outcomes.36 A retrospective analysis stratifying patients with femoropopliteal atherosclerotic disease by low vs. high income reported worse outcomes in the lower income patients, who were also statistically less likely to be taking a statin medication.37

Lower Extremity Revascularization and Outcome for PAD in Women

In Figure 3, we outline the algorithm for the management of PAD in women. The majority of patients with either asymptomatic PAD or intermittent claudication fare well with medical therapy and have a low risk of limb loss. Candidates for revascularization are patients with disabling claudication or those who have evidence of critical limb-threatening ischemia as manifested by the presence of ischemic rest pain, nonhealing wounds, or tissue necrosis. Revascularization can be surgical or endovascular based on the extent of the occlusive lesions and the patient’s clinical characteristics. According to TASC guidelines on PAD treatment
strategies, endovascular revascularization is the treatment of choice for TASC A/B lesions, and surgical intervention is reserved for TASC C/D lesions. However, with evolving technological advances and physician experience, recent reports are demonstrating the efficacy of endovascular treatment for the more extensive TASC C/D lesions.

Numerous cohort studies have shown that women are more likely to be older and present with more advanced disease (critical limb-threatening ischemia and multilevel disease) compared to men.38, 39 Pooled conclusions from large cohort series and review studies have included marginally worse outcomes regarding the rates of limb salvage, morbidity, and mortality for women undergoing lower extremity revascularization when compared to men.40-43 The authors have postulated that the older age, higher rate of diabetes, and more extensive occlusive disease may account for the higher complication rates in women.40-43 In their analysis of the large inpatient discharge database of New York state, Vouyouka et al. reported a slightly higher risk of bleeding (10.6% vs. 8.2%), infection (3.2% vs. 2.9%), and amputations (9.8% vs. 8.8%) in women compared to men undergoing endovascular and open surgical procedures.36 In contrast, other authors have reported equivalent outcomes and limb-salvage rates in women and men, although women presented with more advanced disease.36, 44-46 In our experience, the most challenging revascularization cases for limb salvage have been in women with smaller diameter native vessels, whether using endovascular or open surgical techniques, although this has not been consistently characterized in the literature.

**Aortoiliac Occlusive Disease in Women**

Men and women with aortoiliac occlusive disease are usually half a decade younger than patients with infrainguinal disease at presentation. In general, women have smaller diameter vessels compared to men, a characteristic that is particularly more pronounced in the aortoiliac segments. This may be in part the reason for the reported higher rate of graft thrombosis in women compared to men undergoing aortofemoral bypass. In his experience with aortofemoral reconstructions for 339 men and 197 women over a 28-year period at the Cleveland Clinic, Hertzer et al. reported that women were more likely to sustain graft thrombosis (OR 3.2, P < .005).44 Valentine et al. demonstrated that although women have smaller aortic diameters compared to men, gender was not a predictor for graft failure in a subgroup of younger patients (mean age of 44 years) undergoing surgical aortofemoral revascularization.45 In this study, the mean infrarenal aortic diameter was significantly smaller in the occluded grafts (14.5 mm in women vs. 18.1 mm in men) compared to the patent grafts (15.7 mm vs. 19.2 mm, respectively), indicating the influence of native inflow vessel size on graft patency that is independent of gender.46 In their early experience with endovascular iliac interventions, Ballard et al. showed that aortoiliac artery balloon angioplasty and stenting was inferior to surgical reconstruction in a cohort of 119 women and men.47 Multivariable analysis identified female gender as an independent predictor of bypass graft or stent thrombosis.48 However, the authors did not provide details differentiating between the women with graft thrombosis and those with stent thrombosis. Orr et al. reported their results of iliac angioplasty and stenting for limb salvage in a comparative cohort study of 40 men and 44 women with aortoiliac occlusive disease.49 Despite having smaller iliac arteries (mean luminal diameters of 6.5 mm and 8.2 mm for women and men, respectively) and a higher incidence of native iliac artery occlusion (21% vs. 6%, respectively), women had comparable primary, primary-assisted patency, and limb-salvage rates after a median follow-up of 13 months.49 A subsequent single-institution cohort study compared stenting versus open reconstruction for 169 patients (~39% women) with aortoiliac occlusive disease.50 In this study, the authors showed similar results for limb salvage and immediate-term secondary patency in patients after iliac stenting or open surgery, with no significant gender differences.50

**Infrainguinal Disease in Women**

In a large retrospective study of 5880 patients (37% women) undergoing surgical infrainguinal arterial reconstructions using autogenous venous conduits preferentially, Roddy et al. showed excellent limb salvage rates of 93% for women and 88% for men at 10 years.45 They found no significant differences in long-term survival, primary rate, and secondary patency rates between women and men.44 Similar to other reports, women in this study were significantly older (71 years vs. 66 years), more often diabetic (53% vs. 50%), and less often smokers (27% vs. 44%)

---

*BP: blood pressure; Clinical Surveillance starts over from top to algorithm

**Figure 3.** Algorithm outlining the management of peripheral arterial disease (PAD) in women.
compared to men.41 A more recent report from Ballotta et al. showed comparable excellent results for 496 women and 837 men undergoing open infrainguinal arterial bypass with preferential autogenous vein graft.9 There were no significant differences in morbidity and mortality rates between the two groups despite the fact that women were again a mean 3 years older than men and had a higher incidence of diabetes.30 Ten-year limb salvage rates exceeded 90% in both men and women.30 Other investigators have reported worse limb salvage rates for women of Hispanic and Black races compared to Caucasian women and men.10, 11 Although the underlying explanation for this race-based disparity has yet to be determined, AChong et al. reported poorer primary and secondary graft patency rates in 93 women compared to 98 men undergoing infrainguinal bypass for critical limb ischemia. The authors postulate that the smaller-diameter target artery in women compared to men (median diameter 2.01 mm vs. 2.45 mm, respectively, P = .03) may be contributing, at least in part, to the worse patency outcome.51

Currently, percutaneous endovascular interventions have emerged as the revascularization modality of choice for patients with infrainguinal occlusive disease, including those with critical limb-threatening ischemia. Surgical reconstruction is generally reserved as a second-line or salvage therapy. Several studies have demonstrated low complication rates and good limb-salvage rates following endovascular interventions on occluded femoropopliteal and tibial arteries, with comparable results for men and women.40-52 DeRubertis and coauthors showed equivalent limb salvage and patency rates in women and men undergoing endovascular interventions for infrainguinal occlusive disease, even though the women had a higher prevalence of more advanced TASC C and D lesions (71% vs. 62%) and of critical limb ischemia (62% vs. 47%).30 Puliti et al. showed similar findings with excellent limb salvage rates and low periprocedural complication rates in both women and men.33 As shown in these series and numerous others, endovascular interventions for infrainguinal arterial lesions generally achieve limb salvage rates greater than 80-90%; however, the patency rates remain relatively low compared to those for iliac interventions, averaging a 40-50% primary patency rate at 1 to 2 years and between 50-80% primary-assisted patency rates. It is well recognized that repeated interventions on infrainguinal arterial lesions may be necessary to achieve long-term patency and limb salvage (Figure 4). We find tibial interventions for limb salvage particularly challenging. These patients are often older with multilevel arterial occlusive disease. Target vessels are smaller and less forgiving. In a recent publication, Domenick et al. reported tibial interventions in 201 patients (40% women) and showed an overall limb salvage rate of 88% and a primary patency rate of 62% at one year.53 Gender and age >80 years did not play a significant factor in the outcome.52

We identified two noteworthy reports in the literature indicating that women may have superior outcomes over men following endovascular interventions for infrainguinal arterial occlusive disease. Gallagher et al. reviewed their results of 537 patients (229 male and 308 female) undergoing infrainguinal percutaneous interventions between 2004-2009 and found no differences between genders in lesion characteristics.54 Although women were more likely to have interventions for critical limb ischemia, they actually had better patency rates after interventions for superficial femoral artery and tibial lesions.54 In a recent report by Tye et al., women were also found to have superior primary and patency rates following infrageniculate arterial endovascular interventions.55 In this cohort of 38 men and 43 women, more men had TASC C and D lesions than women. However, female gender remained an independent predictor of superior outcome even after controlling for the gender-related differences in TASC grade.55 All in all, for infrainguinal arterial occlusive disease, there appear to be conflicting findings in the literature with regard to gender disparities in outcome: most studies showed no differences, some demonstrated worse outcomes for women following open surgical revascularization, and some suggested superior results in women with endovascular treatment. Admittedly, some of the published studies may have been underpowered to identify a gender effect on outcomes, which hence underscores the importance for further research.

**Major Lower Extremity Amputation in Women**

Studies have shown lower survival rates for PAD patients requiring lower extremity amputations compared to those with successful revascularization, in part because of selection bias.60, 62 For example, a major leg amputation would be recommended over a revascularization for a patient with high medical risks (Figure 5), and those requiring major amputation are more likely to have more advanced and extensive PAD. There is limited information on gender differences in the incidence and outcome of patients undergoing major lower extremity amputations for ischemic complications. In a literature review, Peek reports on current evidence indicating that men are more likely to undergo diabetes-related lower extremity amputation but that women have higher immediate and long-term mortality after amputation.60 It is estimated that women have more deaths per 1000 amputations compared to men (37.7 vs. 26.7, respectively).61 In addition, men are younger than women at the time of amputation regardless of the level of amputation.60 In one retrospective analysis of the
Nationally Inpatient Sample database for 2007, Lefebvre and Chevan reported that more men had below-knee than above-knee amputation (9% vs. 41%, respectively), whereas more women had above-knee than below-knee amputation (47% vs. 53%, respectively). The authors postulate that the higher rate of above-knee amputations among women may indicate poorer outcomes in the presence of PAD compared to men.

Summary
Although conflicting results can be found in the literature, our review shows that while women with PAD may differ from men in their clinical presentation, their management and outcome are similar. In particular, women have smaller vessels and are older at the time of diagnosis. Future research studies to evaluate pharmacological, surgical, or device-related interventions in limb salvage may enroll women at a rate that reflects the increased prevalence of women with PAD. The widespread adoption of optimal medical management of asymptomatic disease will require large-scale educational efforts directed at both primary care providers and the public to increase the awareness of PAD in women.

Conflict of Interest Disclosure: All authors have completed and submitted the Methodist DeBakey Cardiovascular Journal Conflict of Interest Statement and none were reported.

Funding/Support: The authors have no funding disclosures.

Keywords: limb salvage, peripheral arterial disease, gender, women, ischemia

References
1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011 Feb 1;123(4):e18-e209.
2. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001 Sep 19;286(11):1317-24.
3. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001 May 24;344(21):1608-21.
4. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993 Sep;88(3):837-45.
5. Aronow WS. Peripheral arterial disease in women. Maturitas. 2009 Dec 20;64(4):204-11.
6. Norman PE, Ekelboom JW, Hankey GJ. Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. Med J Aust. 2004 Aug 2;181(3):150-4.
7. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci. 2002 Jan;57(1):M45-6.
8. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992 Feb 6;326(6):381-6.
9. Kröger K, Draganö N, Stang A, Moebs S, Möhlenkamp S, Mann K, et al. An unequal social distribution of peripheral arterial disease and the possible explanations: results from a population-based study. Vasc Med. 2009 Nov;14(4):289-96.
10. Robinson WP 3rd, Owens CD, Nguyen LL, Chong TT, Conte MS, Belkin M. Inferior outcomes of autogenous infrainguinal bypass in Hispanics: an analysis of ethnicity, graft function, and limb salvage. J Vasc Surg. 2009 Jun;49(6):1416-25.
11. Nguyen LL, Hevelone N, Rogers SC, Bandyk DF, Cloves AW, Moneta GL, et al. Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss. Circulation. 2009 Jan 6;119(1):123-30.
12. McDermott MM, Greenland P, Liu K, Criqui MH, Guralnik JM, Celic L, et al. Sex differences in peripheral arterial disease: leg symptoms and physical functioning. J Am Geriatr Soc. 2003 Feb;51(2):222-8.
13. Brevetti G, Piscione F, Cirillo P, Galasso G, Schiano V, Barbato E, et al. In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction. Atherosclerosis. 2008 Dec;201(2):440-6.
14. McDermott MM, Ferrucci L, Liu K, Guralnik JM, Tian L, Kibbe M, et al. Women with peripheral arterial disease experience faster functional decline than men with peripheral arterial disease. J Am Coll Cardiol. 2011 Feb 8;57(6):707-14.
15. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007 Jan;45 Suppl S:S5-67.
16. Dhaliwal G, Mukherjee D. Peripheral arterial disease: Epidemiology, natural history, diagnosis and treatment. Int J Angiol. 2007 Summer;16(2):36-44.
17. Gornik HL, Creager MA. Contemporary management of peripheral arterial disease: I: Cardiovascular risk-factor modification. Cleve Clin J Med. 2006 Oct;73 Suppl 4:S30-7.
18. Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221(3):263-60.
19. Lassila R, Lepäntalo M. Cigarette smoking and the outcome after lower limb artery surgery. Acta Chir Scand. 1988 Nov-Dec;154(11-12):635-40.
20. Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Bütler HR, Prins MH. Smoking and the latency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg. 2005 Jul;42(1):67-74.
21. Patterson RB, Pinto B, Marcus B, Colucci A, Braun T, Roberts M. Value of a supervised exercise program for the therapy of arterial claudication. J Vasc Surg. 1997 Feb;25(2):312-8; discussion 318-9.
22. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005263.
23. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12.
24. Mehler PS, Ciol JR, Estacio R, Ester A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003 Feb 11;107(5):753-6.
25. Nathan DM, Cleary PA, Backlund JY, Genuith SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643-53.
26. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qiong Y, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004 Jan;25(1):17-24.
27. Collaborative overview of randomised trials of antiplatelet therapy – II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists’ Collaboration. BMJ. 1994 Jan 15;308(6922):159-68.

28. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17.

29. Durazzo AE, Machado FS, Ikekoba DT, De Bernoche C, Monachini MC, Ruech-Liao P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg. 2004 May;39(5):967-75; discussion 975-6.

30. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med. 1991 Sep;151(9):1769-76.

31. Faggotto A, Padgett R. State-of-the-Art lecture. Stains and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension. 1999 Oct;34(4 Pt 2):987-96.

32. Sukhija R, Yalamanchili K, Aronow WS, Kabir P, Babu S. Clinical characteristics, risk factors, and medical treatment of 561 patients with peripheral arterial disease followed in an academic vascular surgery clinic. Cardiovasc Rev. 2005 Mar-Apr;13(2):105-10.

33. Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg. 2002 Mar-Apr;36(2):83-91.

34. Dawson DL, Culler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2001 Jun;82(6):797-800.

35. Nguyen L, Liles DR, Lin PH, Bush RL. Hormone replacement therapy and peripheral vascular disease in women. Vasc Endovascular Surg. 2004 Nov-Dec;38(6):547-56.

36. Vouyouka AG, Egorova NN, Salourn A, Kleinman L, Marin M, Faries PL, et al. Lessons learned from the analysis of gender effect on risk factors and procedural outcomes of lower extremity arterial disease. J Vasc Surg. 2010 Nov;52(5):1196-202.

37. Durham CA, Mohr MC, Parker FM, Bogey WM, Powell CS, Stone MC. The impact of socioeconomic factors on outcome and hospital costs associated with femoropopliteal occlusive disease. J Vasc Surg. 2002 Jan;35(1):157-8.

38. Ballard JL, Bergan JJ, Singh P, Yonomoto H, Killeen JD. Aorticiliac stent grafting: outcomes of 250 consecutive cases. J Vasc Interv Radiol. 2013 Dec;24(12):1973-80.

39. Ortmann J, Nüesch E, Traupe T, Diehm N, Baumgartner I. Gender-related outcomes in the endovascular treatment of infrainguinal peripheral artery disease. J Vasc Surg. 2012 Oct;56(4):937-45.

40. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17.

41. Hertzer NR, Bena JF, Karafa MT. A personal experience with aorticiliac stent grafting: outcomes of 250 consecutive cases. J Vasc Interv Radiol. 2013 Dec;24(12):1973-80.

42. Hirsch AT, Allison MA, Gomes AS, Corriere MA, Duval S, Ershow AG, et al. A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Circulation. 2012 Mar 20;125(11):1449-72.

43. Mays BW, Towne JB, Fitzpatrick CM, Smart SC, Cambria RA, Seabrook GR, et al. Women have increased risk of perioperative myocardial infarction and higher long-term mortality rates after lower extremity arterial bypass grafting. J Vasc Surg. 1999 May;29(5):807-12; discussion 812-3.

44. Kumakura H, Kanai H, Araki Y, Kasama S, Sumino H, Ito T, et al. Sex-related differences in Japanese patients with peripheral arterial disease. Atherosclerosis. 2011 Dec;219(2):846-50.

45. Roddy SP, Darling RC 3rd, Maharaj D, Chang BB, Paty PS, Kreienberg PB, et al. Gender-related differences in outcome: an analysis of 5580 infrainguinal arterial reconstructions. J Vasc Surg. 2003 Feb;37(2):399-402.

46. DeRubertis BG, Vouyouka A, Rhee SJ, Califano J, Karwowski J, Angle N, et al. Percutaneous intervention for infrainguinal occlusive disease in women: equivalent outcomes despite increased severity of disease compared with men. J Vasc Surg. 2008 Jul;48(1):150-7; discussion 157-8.

47. Hertzer NR, Bena JF, Karafa MT. A personal experience with the influence of diabetes and other factors on the outcome of infrainguinal bypass grafts for occlusive disease. J Vasc Surg. 2007 Aug;46(2):271-9.

48. Valentine RJ, Hansen ME, Myers SL, Cheruvu A, Clagett GP. The influence of sex and aortic size on late patency after aortofemoral revascularization in young adults. J Vasc Surg. 1995 Feb;21(2):296-305; discussion 305-6.

49. Orr JD, Leeper NJ, Funaki B, Leef J, Gewertz BL, Desai TR. Gender does not influence outcomes after iliac angioplasty. Ann Vasc Surg. 2002 Jan;16(1):55-60.

50. Kashyap VS, Pavkov ML, Bena JF, Sarac TP, O’Hara PJ, Lyden SP, et al. The management of severe aortoiliac occlusive disease: endovascular therapy rivals open reconstruction. J Vasc Surg. 2002 Dec;36(6):1451-2; discussion 1457-8.

51. AhChong AK, Chiu KM, Wong M, Yip AW. The influence of gender difference on the outcomes of infrainguinal bypass for critical limb ischaemia in Chinese patients. Eur J Vasc Endovasc Surg. 2002 Feb;23(2):134-9.

52. Domenick N, Saqib NU, Marone LK, Rhee MY, Makaroun MS, Chae RA. Impact of gender and age on outcomes of tibial artery endovascular interventions in critical limb ischaemia. Ann Vasc Surg. 2012 Oct;26(7):937-45.

53. Pulli R, Dorigo W, Pratesi G, Fargion A, Angelletta D, Pratesi C. Gender-related outcomes in the endovascular treatment of infrainguinal arterial obstructive disease. J Vasc Surg. 2012 Jan;55(1):105-12.

54. Gallagher KA, Meltzer AJ, Ravin RA, Graham A, Connolly P, Escobar G, et al. Gender differences in outcomes of endovascular treatment of infrainguinal peripheral arterial disease. Vasc Endovascular Surg. 2011 Nov;45(8):703-11.

55. Tye A, Han DK, Tadros RO, Spyris CT, Teodorescu V, Marin ML, et al. Percutaneous intervention for infrageniculate arterial disease in women may be associated with better outcomes when compared to men. J Vasc Surg. 2013 Mar;57(3):706-13.

56. Abou-Zamzam AM Jr, Gomez MR, Molkara A, Banta JE, Teruya TH, Killeen JD, et al. A prospective analysis of critical limb ischaemia: factors leading to major primary amputation versus revascularization. Ann Vasc Surg. 2007 Jul;21(4):458-63.

57. Oriel K, Fiore WM, Geary JE. Limb-threatening ischaemia in the medically compromised patient: amputation or revascularization? Arch Phys Med Rehabil. 1991 Nov;72(11):1265-9.

58. Peek ME. Gender differences in diabetes-related lower extremity amputations. Clin Orthop Relat Res. 2011 Jul;469(7):1951-5.

59. Lefebvre KM, Chevan J. Sex disparities in level of amputation. Arch Phys Med Rehabil. 2011 Jan;92(1):118-24.